Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/Ml

Catàlona, William J.; Bartsch, Georg; Rittenhouse, Harry G.; Evans, Cindy L.; Linton, Harry J.; Amirkhan, Anna; Horninger, Wolfgang; Klocker, Helmut; Mikolajczyk, Stephen D.

doi:10.1097/01.ju.0000095460.12999.43

Cited by 151 publications

(86 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sokoll and Catalona found that the percentage of pro-PSA could significantly decrease the number of unnecessary biopsies in men with a PSA between 2 and 4 ng ml À1 . 47,48 Moreover, 2-pro-PSA, a truncated form of pro-PSA, had the highest specificity for PCa screening and was the most efficient predictor of PCa aggressiveness. 49 Intact free PSA is similar to native PSA, but enzymatically inactive.…”

Section: Free Psa Isoformsmentioning

confidence: 99%

New circulating biomarkers for prostate cancer

Bensalah

Lotan

Karam

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Section: Free Psa Isoformsmentioning

confidence: 99%

New circulating biomarkers for prostate cancer

Bensalah

Lotan

Karam

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…48 -50 Other PSA isoforms have been reported to be related to the risk of prostate carcinoma detection. 51,52 These observations have modulated recommendations for prostate biopsy in some settings. Most often, these factors have affected recommendations for a repeat prostate biopsy after an initial negative biopsy.…”

Section: Psa Isoformsmentioning

confidence: 99%

Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

Hernández

Thompson

2004

Cancer

280

173

View full text Add to dashboard Cite

Objective To review the literature and collect expert advice for proposing preventive and curative treatments of mouth and dental involvement in patients with systemic sclerosis (SSc; scleroderma). Methods The literature pertaining to mouth and/or dental involvement related to SSc was reviewed, and recommendations were developed according to the suggestions of a French multidisciplinary working group of experts and validated by a lecture committee. Results Dentists face 3 main issues in caring for SSc patients: oral mucosa involvement, manducatory apparatus and mouth involvement responsible for limitations in mouth opening, and treatment‐related adverse events. An increased risk of tongue carcinoma has been noted. In patients with severe limitation in mouth opening (<30 mm), recommended treatments are a specific mouth‐opening rehabilitation program, flexible sectional dentures, and splint therapy. Indications for dental implants depend on the severity of SSc, comorbidities, and/or ongoing bisphosphonate treatment. Prevention of mouth infections and caries implies patient education and teaching about mouth and dental hygiene, periodontal maintenance, and treatment of sicca syndrome. Cessation of tobacco use is mandatory. Patient‐tailored rehabilitation may improve limitations in mouth opening. Systematic dental panoramic radiography allows for the early detection of dental caries. Conclusion Prevention of oral and dental complications is a major issue in patients with SSc. Dental treatment should be tailored to limitations in mouth opening, disease severity, and ongoing treatments.

show abstract

“…[14] Naya et al [37] , indicated lack of any significant difference between patients with or without PCa as for pPSA values, and % pPSA within a tPSA interval 4.4-8.5 ng/mL. Catalona et al [38] observed increases in % pPSA values in PCa patients with tPSA values varying between 2, and 10 ng/mL, and stated that % pPSA has higher diagnostic sensitivity, and specificity for PCa when compared with % fPSA without any correlation between histopathological stage, and % pPSA. Mikolajczyk et al [39] also pointed out to higher specificity, and positive predictive value of % pPSA rather than % fPSA for PCa in cases with tPSA values between 4, and 10 ng/mL.…”

Section: Propsa (Ppsa)mentioning

confidence: 99%

PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer

Ayyıldız¹,

Ayyıldız²

2014

Turkish Journal of Urology

View full text Add to dashboard Cite

Currently, prostate-specific antigen (PSA) is the most common oncological marker used for prostate cancer screening. However, high levels of PSA in benign prostatic hyperplasia and prostatitis decrease the specificity of PSA as a cancer marker. To increase the specificity of PSA, PSA derivatives and PSA kinetics have been used. However, these new techniques were not able to increase the diagnostic specificity for prostate cancer.Therefore, the search for new molecules and derivatives of PSA continues. With the aim of increasing the specificity of prostate cancer diagnosis, proPSA and the Prostate Health Index have been introduced. In this review, the roles of PSA, PSA derivatives, proPSA and the Prostate Health Index in Prostate Cancer diagnosis are examined.

show abstract

Serum Pro Prostate Specific Antigen Improves Cancer Detection Compared to Free and Complexed Prostate Specific Antigen in Men With Prostate Specific Antigen 2 to 4 Ng/Ml

Abstract: The %pPSA significantly improved specificity for cancer detection and decreased the number of unnecessary biopsies in the PSA 2 to 4 ng/ml range. This relative improvement of %pPSA compared to % free PSA and complexed PSA was maintained throughout the PSA range of 2 to 10 ng/ml.

Cited by 151 publications

References 18 publications

New circulating biomarkers for prostate cancer

New circulating biomarkers for prostate cancer

Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker

PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer

Contact Info

Product

Resources

About